Literature DB >> 24170027

Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.

F Arruga1, B Gizdic2, S Serra3, T Vaisitti1, C Ciardullo4, M Coscia5, L Laurenti6, G D'Arena7, O Jaksic8, G Inghirami9, D Rossi4, G Gaidano4, S Deaglio3.   

Abstract

The purpose of this study was to compare the expression and function of NOTCH1 in chronic lymphocytic leukemia (CLL) patients harboring a wild-type (WT) or mutated NOTCH1 gene. NOTCH1 mRNA and surface protein expression levels were independent of the NOTCH1 gene mutational status, consistent with the requirement for NOTCH1 signaling in this leukemia. However, compared with NOTCH1-WT CLL, mutated cases displayed biochemical and transcriptional evidence of an intense activation of the NOTCH1 pathway. In vivo, expression and activation of NOTCH1 was highest in CLL cells from the lymph nodes as confirmed by immunohistochemistry. In vitro, the NOTCH1 pathway was rapidly downregulated, suggesting that signaling relies upon micro-environmental interactions even in NOTCH1-mutated cases. Accordingly, co-culture of Jagged1(+) (the NOTCH1 ligand) nurse-like cells with autologous CLL cells sustained NOTCH1 activity over time and mediated CLL survival and resistance against pro-apoptotic stimuli, both abrogated when NOTCH1 signaling was pharmacologically switched off. Together, these results show that NOTCH1 mutations have stabilizing effects on the NOTCH1 pathway in CLL. Furthermore, micro-environmental interactions appear critical in activating the NOTCH1 pathway both in WT and mutated patients. Finally, NOTCH1 signals may create conditions that favor drug resistance, thus making NOTCH1 a potential molecular target in CLL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24170027     DOI: 10.1038/leu.2013.319

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  53 in total

1.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

2.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

Review 3.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

4.  Activity of the notch-signalling pathway in circulating human chronic lymphocytic leukaemia cells.

Authors:  M Hajdu; A Sebestyén; G Barna; L Reiniger; J Jánosi; L Sréter; J Várkonyi; J Demeter; L Kopper
Journal:  Scand J Immunol       Date:  2007-03       Impact factor: 3.487

5.  NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.

Authors:  N Villamor; L Conde; A Martínez-Trillos; M Cazorla; A Navarro; S Beà; C López; D Colomer; M Pinyol; M Aymerich; M Rozman; P Abrisqueta; T Baumann; J Delgado; E Giné; M González-Díaz; J M Hernández; E Colado; A R Payer; C Rayon; B Navarro; M José Terol; F Bosch; V Quesada; X S Puente; C López-Otín; P Jares; A Pereira; E Campo; A López-Guillermo
Journal:  Leukemia       Date:  2012-12-06       Impact factor: 11.528

6.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

7.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Authors:  David G Oscier; Matthew J J Rose-Zerilli; Nils Winkelmann; David Gonzalez de Castro; Belen Gomez; Jade Forster; Helen Parker; Anton Parker; Anne Gardiner; Andrew Collins; Monica Else; Nicholas C P Cross; Daniel Catovsky; Jonathan C Strefford
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

10.  Signalling downstream of activated mammalian Notch.

Authors:  S Jarriault; C Brou; F Logeat; E H Schroeter; R Kopan; A Israel
Journal:  Nature       Date:  1995-09-28       Impact factor: 49.962

View more
  45 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

Review 2.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

4.  Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.

Authors:  Arantza Onaindia; Sagrario Gómez; Miguel Piris-Villaespesa; Carolina Martínez-Laperche; Laura Cereceda; Santiago Montes-Moreno; Ana Batlle; Sonia González de Villambrosia; Marina Pollán; Paloma Martín-Acosta; Julia González-Rincón; Javier Menarguez; Javier Alvés; Socorro M Rodriguez-Pinilla; Juan F García; Manuela Mollejo; Máximo Fraga; José A García-Marco; Miguel A Piris; Margarita Sánchez-Beato
Journal:  Haematologica       Date:  2014-12-31       Impact factor: 9.941

5.  NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Authors:  F Pozzo; T Bittolo; F Arruga; P Bulian; P Macor; E Tissino; B Gizdic; F M Rossi; R Bomben; A Zucchetto; D Benedetti; M Degan; G D'Arena; A Chiarenza; F Zaja; G Pozzato; D Rossi; G Gaidano; G Del Poeta; S Deaglio; V Gattei; M Dal Bo
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

6.  Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia.

Authors:  Giulia Fabbri; Antony B Holmes; Mara Viganotti; Claudio Scuoppo; Laura Belver; Daniel Herranz; Xiao-Jie Yan; Yasmine Kieso; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Adolfo A Ferrando; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-17       Impact factor: 11.205

7.  Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.

Authors:  Matteo Marchesini; Andrea Gherli; Anna Montanaro; Laura Patrizi; Claudia Sorrentino; Luca Pagliaro; Chiara Rompietti; Samuel Kitara; Sabine Heit; Claus E Olesen; Jesper V Møller; Monia Savi; Leonardo Bocchi; Rocchina Vilella; Federica Rizzi; Marilena Baglione; Giorgia Rastelli; Caterina Loiacono; Roberta La Starza; Cristina Mecucci; Kimberly Stegmaier; Franco Aversa; Donatella Stilli; Anne-Marie Lund Winther; Paolo Sportoletti; Maike Bublitz; William Dalby-Brown; Giovanni Roti
Journal:  Cell Chem Biol       Date:  2020-05-07       Impact factor: 8.116

8.  Clonal dynamics in chronic lymphocytic leukemia.

Authors:  Catherine Gutierrez; Catherine J Wu
Journal:  Blood Adv       Date:  2019-11-26

9.  NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Authors:  D Benedetti; E Tissino; F Pozzo; T Bittolo; C Caldana; C Perini; D Martorelli; V Bravin; T D'Agaro; F M Rossi; R Bomben; E Santinelli; F Zaja; G Pozzato; A Chiarenza; F Di Raimondo; G Del Poeta; D Rossi; G Gaidano; M Dal Bo; V Gattei; A Zucchetto
Journal:  Leukemia       Date:  2017-09-22       Impact factor: 11.528

10.  Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.

Authors:  F Arruga; B Gizdic; C Bologna; S Cignetto; R Buonincontri; S Serra; T Vaisitti; K Gizzi; N Vitale; G Garaffo; E Mereu; F Diop; F Neri; D Incarnato; M Coscia; J Allan; R Piva; S Oliviero; R R Furman; D Rossi; G Gaidano; S Deaglio
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.